Penumbra’s CAVT technology shows benefits in pulmonary embolism

Penumbra (PEN) announced new data that demonstrate patients with intermediate-risk pulmonary embolism – PE – treated with Penumbra’s computer assisted vacuum thrombectomy, or CAVT, technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances 2024 Conference. When compared to other modalities studied, the data showed that CAVT resulted in 25%-35% shorter total hospital length of stay, 25%-30% higher average rate of patients discharged home, and 2-3 times fewer average composite complications. In the study, CAVT was associated with improvement in contribution margin relative to anticoagulation alone. An example given was that if 10% more patients are treated with CAVT, hospitals could see up to a 75% gain in profitable contribution margin, representing thousands of dollars more per patient vs. treatment with anticoagulation alone.